RG7774 (Vicasinabin), an orally bioavailable cannabinoid receptor 2 (CB2R) agonist, decreases retinal vascular permeability, leukocyte adhesion, and ocular inflammation in animal models.

Saved in:
Bibliographic Details
Title: RG7774 (Vicasinabin), an orally bioavailable cannabinoid receptor 2 (CB2R) agonist, decreases retinal vascular permeability, leukocyte adhesion, and ocular inflammation in animal models.
Authors: Grether U; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Foxton RH; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Gruener S; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Korn C; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Kimbara A; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Osterwald A; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Zirwes E; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Uhles S; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Thoele J; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Colé N; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Rogers-Evans M; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Röver S; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Nettekoven M; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Martin RE; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Adam JM; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Fingerle J; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Bissantz C; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Guba W; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Alker A; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Szczesniak AM; Departments of Pharmacology, Anesthesia, Ophthalmology and Visual Sciences, Dalhousie University, Halifax, NS, Canada., Porter RF; Departments of Pharmacology, Anesthesia, Ophthalmology and Visual Sciences, Dalhousie University, Halifax, NS, Canada., Toguri TJ; Departments of Pharmacology, Anesthesia, Ophthalmology and Visual Sciences, Dalhousie University, Halifax, NS, Canada., Revelant F; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Poirier A; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Perret C; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Winther L; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Caruso A; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Fezza F; Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy., Maccarrone M; Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.; European Center for Brain Research (CERC), Santa Lucia Foundation IRCCS, Rome, Italy., Kelly MEM; Departments of Pharmacology, Anesthesia, Ophthalmology and Visual Sciences, Dalhousie University, Halifax, NS, Canada., Fauser S; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland., Ullmer C; F. Hoffmann-La Roche Ltd, Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
Source: Frontiers in pharmacology [Front Pharmacol] 2024 Jul 12; Vol. 15, pp. 1426446. Date of Electronic Publication: 2024 Jul 12 (Print Publication: 2024).
Publication Type: Journal Article
Journal Info: Publisher: Frontiers Media] Country of Publication: Switzerland NLM ID: 101548923 Publication Model: eCollection Cited Medium: Print ISSN: 1663-9812 (Print) Linking ISSN: 16639812 NLM ISO Abbreviation: Front Pharmacol Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1663-9812
DOI:10.3389/fphar.2024.1426446